Iort denied due to quantity / dose limits by Aetna?
Quantity-limit denials usually flip when the appeal documents the clinically appropriate dose for the patient's weight, kidney function, or escalation schedule, citing the FDA label or specialty-society guideline.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Aetna typically requires
Aetna considers IORT medically necessary for select early-stage breast cancer patients meeting TARGIT-A inclusion criteria: age ≥50, unifocal invasive ductal carcinoma, T1 (≤2cm), node-negative, hormone-receptor positive, HER2-negative, no extensive intraductal component. IORT may be delivered as single-fraction at lumpectomy (boost) or as primary partial-breast irradiation. Aetna considers IORT investigational/experimental for most non-breast indications (rectal, glioblastoma, sarcoma, recurrent rectal/pelvic) absent specific guideline support.
What works in the appeal
TARGIT-A 5-yr long-term (Vaidya BMJ 2020;370:m2836) — non-inferior local control vs WBRT for selected patients meeting TARGIT-A criteria, sustained at 12-yr follow-up (Vaidya 2024). ELIOT 5-yr + 10-yr (Veronesi Lancet Oncol 2013;14:1269; Orecchia 2021) — Italian electron IORT outcomes for selected low-risk profile. GEC-ESTRO consensus on partial-breast irradiation 2010/2024 update (Strnad). ASTRO APBI Consensus Statement 2017/update — IORT category eligibility table. NCCN Breast Cancer v2.2024 lists IORT as APBI option meeting selection criteria. For rectal IORT cite NCCN Rectal Cancer v3.2024 (locally advanced + R0 close margin) and Calvo et al EJC 2014 IORT outcomes. Document staging completion (sentinel node, IHC), final pathology with margins, multidisciplinary tumor board recommendation. Submit ABS / ASTRO / ASCO position statements where applicable.
The Aetna angle on Iort
## Why Aetna Limits Intraoperative Radiation Therapy Quantity — and How to Appeal
A quantity-limits denial for Intraoperative Radiation Therapy (IORT) from Aetna typically arises when the plan's coverage policy restricts IORT to a single treatment session per surgical episode, or to a specific number of fractions, and the request exceeds that limit. In some cases it may reflect a coding issue where multiple procedure codes triggered a quantity flag. Understanding exactly what quantity restriction was applied is the first step.
## Why This Denial Is Appealable
IORT is by its nature an intraoperative procedure — typically delivered as a single, precisely targeted application during surgery. If the quantity-limits denial reflects a misinterpretation of the procedure (for example, flagging a single IORT session as exceeding a limit designed for a different modality), the appeal can resolve it with clear documentation. If the treating team has a legitimate clinical rationale for the quantity requested — such as an unusual surgical scenario requiring multiple fields — the appeal must document that clinical rationale specifically and explain why it is consistent with accepted radiation oncology practice.
## Federal Appeal Framework
- Internal appeal: File under ERISA §503 or applicable state law within the deadline on the denial notice. Request the specific quantity limit applied and the plan provision authorizing it.
- External review: After exhausting internal appeals, escalate under ACA §2719 to an independent IRO within four months of the final adverse determination.
- Expedited review: If surgery is scheduled and the denial would prevent timely care, request expedited review — decisions are typically required within 72 hours.
## Documentation to Gather
- Denial specifics: The exact procedure code(s) flagged, the quantity limit applied, and the plan language cited.
- Radiation oncology treatment plan: The written treatment plan from the radiation oncologist explaining what was performed or planned, why, and how it aligns with accepted IORT technique for the diagnosis.
- Operative or procedural report: Documentation of what was actually done during surgery, confirming the quantity and clinical context.
- Treating oncologist's letter: A letter from the radiation oncologist explaining the clinical rationale for the quantity of IORT applied and citing the applicable professional society guideline supporting that approach.
- Diagnosis and staging: Pathology, staging, and tumor-characteristic documentation establishing the clinical context.
## Criteria-Mapping Structure
Pull the exact quantity-limit language from Aetna's published IORT clinical policy. If the limit appears designed for a different radiation modality and was applied to IORT in error, document that mismatch explicitly. If the quantity is clinically justified, map each relevant policy criterion to the corresponding surgical or oncologic documentation. A clear, structured response that addresses the specific quantity-limit provision — rather than a general medical-necessity argument — is most likely to succeed at the internal review stage.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →